09:46 AM EDT, 04/11/2024 (MT Newswires) -- Candel Therapeutics ( CADL ) shares jumped 27.5% in recent trading Thursday after the company said its potential treatment for pancreatic cancer CAN-2409 has received orphan drug designation from the US Food and Drug Administration.

Recently reported data from a phase 2 clinical trial showed that when added to standard of care, CAN-2409 "more than doubled the median overall survival" achieved with standard of care alone, said Candel Chief Executive Paul Peter Tak.

Price: 6.50, Change: +1.40, Percent Change: +27.50